Vanguard Group Inc. Has $236.07 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Vanguard Group Inc. raised its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 10,263,815 shares of the biopharmaceutical company’s stock after purchasing an additional 131,087 shares during the quarter. Vanguard Group Inc. owned approximately 0.11% of Ultragenyx Pharmaceutical worth $236,068,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in RARE. Jacobs Levy Equity Management Inc. increased its holdings in Ultragenyx Pharmaceutical by 614.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Ultragenyx Pharmaceutical by 3.9% during the third quarter. Wellington Management Group LLP now owns 1,945,129 shares of the biopharmaceutical company’s stock worth $58,509,000 after buying an additional 73,309 shares during the last quarter. Aberdeen Group plc boosted its holdings in Ultragenyx Pharmaceutical by 51.0% during the fourth quarter. Aberdeen Group plc now owns 1,469,951 shares of the biopharmaceutical company’s stock worth $33,809,000 after buying an additional 496,295 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Ultragenyx Pharmaceutical by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 1,255,203 shares of the biopharmaceutical company’s stock worth $45,639,000 after buying an additional 7,823 shares during the period. Finally, GW&K Investment Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 139.0% during the 3rd quarter. GW&K Investment Management LLC now owns 1,150,169 shares of the biopharmaceutical company’s stock worth $34,597,000 after buying an additional 668,881 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 0.0%

RARE opened at $26.12 on Friday. The stock has a market capitalization of $2.57 billion, a P/E ratio of -4.27 and a beta of 0.39. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37. The firm’s fifty day simple moving average is $22.68 and its 200 day simple moving average is $26.80.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 2,272.48% and a negative net margin of 91.03%.The firm had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter last year, the company posted ($1.57) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% on a year-over-year basis. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on RARE shares. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. HC Wainwright lowered their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Morgan Stanley raised their price objective on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Finally, Wedbush reduced their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.41.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $185,478.00. Following the sale, the executive vice president owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Erik Harris sold 10,539 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $240,289.20. Following the completion of the sale, the executive vice president owned 89,515 shares in the company, valued at $2,040,942. The trade was a 10.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 111,522 shares of company stock valued at $2,543,214 over the last ninety days. Company insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.